IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Versant Venture Management, LLC

Q1 2018 Holdings

Filed 2018-05-03 | 8 holdings | $312.7M | 13F-HR | View on SEC ↗ · Holdings Table ↗

Sign in to see sub-manager breakdown

IssuerClassCUSIPValue ↓Shares% Portfolio
Crispr Therapeutics AG(CRSP)Common StockH17182108$210.6M4,606,24267.3%
Audentes Therapeutics, Inc.(BOLDEUR)Common Stock05070R104$36.2M1,204,61511.6%
Achaogen, Inc.Common Stock004449104$16.6M1,281,1525.3%
Ocular Therapeutix, Inc.(OCUL)Common Stock67576A100$14.4M2,215,3844.6%
CymaBay Therapeutics, Inc.(CBAYUSD)Common Stock23257D103$13.6M1,048,6014.4%
Second Sight Medical Products, Inc.Common Stock81362J100$8.6M4,492,9752.8%
ImmuneDesign Corp.Common Stock45252L103$7.3M2,208,2102.3%
Clovis Oncology, Inc.(CLVSEUR)Common Stock189464100$5.4M101,8551.7%